An abrupt aversion to sex is a common, albeit lesser-known, complication of taking GLP-1 medications, such as Mounjaro, ...

A new study adds to a growing body of evidence that semaglutide has benefits other than weight loss or controlling diabetes.

Over 40% of U.S. adults meet the medical classification for obesity, according to the Centers for Disease Control and ...

A small study confirms observations what users have observed: the medications reduce their cravings for alcohol.

Semaglutide's role extends beyond diabetes, aiding weight loss and offering cardiovascular protection, with ongoing research ...

In 2022, when the surge in popularity of the GLP-1 class of weight loss and diabetes drugs really began, stories of surprise ...

They are doing it not primarily for weight loss — the effect that has made Ozempic a Hollywood staple ... injecting the regular introductory weekly dose, people are only taking half that amount ...

Results of a placebo-controlled trial support prior observational findings that GLP-1 agonists can help reduce alcohol ...

Among those who adhered to treatment, the high-dose group achieved an average weight loss of 20.7% ... semaglutide products – Ozempic and Rybelsus for type 2 diabetes – have been included ...

The drug semaglutide has been linked to a lower risk of alcoholism before, but now we have strong evidence that it really ...

However, after stopping Ozempic, it could take your body about 5 weeks after your last dose ... type 2 diabetes. Another diabetes drug, Saxenda (liraglutide), is approved for weight loss in ...

which it believes has the potential to redefine the market for weight-loss medicines. Already approved at a lower dose as Ozempic for treating diabetes, the new 2.4 mg once-weekly formulation ...